Abstract
NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin-(1-7), AT1 receptor blockers, bradykinin, dihydropyridine calcium channel blockers, statins, endothelial nitric oxide synthase, nitric oxide, transcriptional and posttranscriptional regulation.
Current Pharmaceutical Design
Title:Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Volume: 23 Issue: 40
Author(s): Jin Bo Su*
Affiliation:
- Universite Paris-Est Creteil Val-de-Marne, 94700, Creteil,France
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin-(1-7), AT1 receptor blockers, bradykinin, dihydropyridine calcium channel blockers, statins, endothelial nitric oxide synthase, nitric oxide, transcriptional and posttranscriptional regulation.
Abstract: NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.
Export Options
About this article
Cite this article as:
Su Bo Jin*, Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666170622112253
DOI https://dx.doi.org/10.2174/1381612823666170622112253 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluid Retention and Rostral Fluid Shift in Sleep-Disordered Breathing
Current Hypertension Reviews Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Prediction and Targeting of Interaction Interfaces in G-protein Coupled Receptor Oligomers
Current Topics in Medicinal Chemistry Sugammadex, a Promising Reversal Drug. A Review of Clinical Trials
Reviews on Recent Clinical Trials Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry The Gender Bender effect in Periodontal Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Current Status of Antiplatelet Therapy in Acute Coronary Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Towards More Efficient Glutathione Peroxidase Mimics: Substrate Recognition and Catalytic Group Assembly
Current Medicinal Chemistry New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Part 1: The Wider Considerations in Translating Heart Failure Guidelines
Current Cardiology Reviews Can Decision Making Research Provide a Better Understanding of Chemical and Behavioral Addictions?
Current Drug Abuse Reviews